GB0303319D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0303319D0
GB0303319D0 GBGB0303319.8A GB0303319A GB0303319D0 GB 0303319 D0 GB0303319 D0 GB 0303319D0 GB 0303319 A GB0303319 A GB 0303319A GB 0303319 D0 GB0303319 D0 GB 0303319D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
gsk
pkc
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0303319.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0303319.8A priority Critical patent/GB0303319D0/en
Publication of GB0303319D0 publication Critical patent/GB0303319D0/en
Priority to CNB2004800029076A priority patent/CN100439359C/zh
Priority to ES09004073T priority patent/ES2385071T3/es
Priority to BRPI0407512-9A priority patent/BRPI0407512A/pt
Priority to US10/542,175 priority patent/US7820672B2/en
Priority to EP09004073A priority patent/EP2075249B1/en
Priority to JP2005518422A priority patent/JP2006515004A/ja
Priority to PCT/EP2004/001323 priority patent/WO2004072062A2/en
Priority to ES04710393T priority patent/ES2343115T3/es
Priority to EP04710393A priority patent/EP1597250B8/en
Priority to AT04710393T priority patent/ATE463491T1/de
Priority to DE602004026415T priority patent/DE602004026415D1/de
Priority to CA002513613A priority patent/CA2513613A1/en
Priority to PT04710393T priority patent/PT1597250E/pt
Priority to AT09004073T priority patent/ATE551335T1/de
Priority to JP2009165725A priority patent/JP2009280592A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
GBGB0303319.8A 2003-02-13 2003-02-13 Organic compounds Ceased GB0303319D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0303319.8A GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds
AT09004073T ATE551335T1 (de) 2003-02-13 2004-02-12 Indolylmaleimid-derivate
JP2005518422A JP2006515004A (ja) 2003-02-13 2004-02-12 インドリルマレイミド誘導体
ES04710393T ES2343115T3 (es) 2003-02-13 2004-02-12 Derivados de indolilmaleimida.
BRPI0407512-9A BRPI0407512A (pt) 2003-02-13 2004-02-12 derivados de indolilmaleimida
US10/542,175 US7820672B2 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
EP09004073A EP2075249B1 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
CNB2004800029076A CN100439359C (zh) 2003-02-13 2004-02-12 吲哚基马来酰亚胺衍生物
PCT/EP2004/001323 WO2004072062A2 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
ES09004073T ES2385071T3 (es) 2003-02-13 2004-02-12 Derivados de indolilmaleimida
EP04710393A EP1597250B8 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
AT04710393T ATE463491T1 (de) 2003-02-13 2004-02-12 Indolylmaleimid derivate
DE602004026415T DE602004026415D1 (de) 2003-02-13 2004-02-12 Indolylmaleimid derivate
CA002513613A CA2513613A1 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
PT04710393T PT1597250E (pt) 2003-02-13 2004-02-12 Derivados indolilmaleimida
JP2009165725A JP2009280592A (ja) 2003-02-13 2009-07-14 インドリルマレイミド誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303319.8A GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds

Publications (1)

Publication Number Publication Date
GB0303319D0 true GB0303319D0 (en) 2003-03-19

Family

ID=9952961

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0303319.8A Ceased GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds

Country Status (12)

Country Link
US (1) US7820672B2 (enExample)
EP (2) EP2075249B1 (enExample)
JP (2) JP2006515004A (enExample)
CN (1) CN100439359C (enExample)
AT (2) ATE463491T1 (enExample)
BR (1) BRPI0407512A (enExample)
CA (1) CA2513613A1 (enExample)
DE (1) DE602004026415D1 (enExample)
ES (2) ES2343115T3 (enExample)
GB (1) GB0303319D0 (enExample)
PT (1) PT1597250E (enExample)
WO (1) WO2004072062A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006019732D1 (de) 2005-07-11 2011-03-03 Novartis Ag Indolylmaleimidderivate
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2094689B1 (en) * 2006-12-19 2013-04-03 Novartis AG Indolylmaleimide derivatives as kinase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101671329B (zh) * 2009-06-17 2012-11-07 东华大学 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用
CA2892927A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
CN104693198B (zh) * 2014-12-13 2017-03-08 浙江工业大学 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
AU2016364889B2 (en) 2015-12-02 2024-01-04 Agenus Inc. Antibodies and methods of use thereof
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN110551103B (zh) * 2018-05-30 2022-08-23 北京大学深圳研究生院 一种jak3选择性抑制剂
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629947B2 (ja) 1986-07-16 1994-04-20 正浩 入江 光学記録材料
IL89167A (en) 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
JPH06161024A (ja) 1992-11-26 1994-06-07 Sanyo Electric Co Ltd 光学記録材料
US5405864A (en) 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
US5559228A (en) 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
JPH0961647A (ja) 1995-08-25 1997-03-07 Nippon Telegr & Teleph Corp <Ntt> 光素子用有機材料
FR2772266B1 (fr) 1997-12-12 2000-02-04 Oreal Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant
EP1119548B1 (en) 1998-10-08 2004-12-08 SmithKline Beecham plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6359150B1 (en) 1999-08-31 2002-03-19 Kyocera Corporation Photochromic compound and optical function device using the same
AU1189201A (en) 1999-10-22 2001-05-08 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
US6281356B1 (en) 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
MXPA02011079A (es) 2000-05-11 2004-08-19 Consejo Superior Investigacion Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
ATE284885T1 (de) 2000-07-27 2005-01-15 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren
KR100748386B1 (ko) 2000-11-07 2007-08-10 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
JP2002285146A (ja) 2001-03-27 2002-10-03 Masahiro Irie フォトクロミック組成物及び線量計
DE60209471D1 (de) 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
BE1014306A6 (fr) 2001-07-19 2003-08-05 Project 21C Dispositif de stationnement d'un cycle avec antivol.
WO2003076398A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida

Also Published As

Publication number Publication date
US20060058356A1 (en) 2006-03-16
ATE551335T1 (de) 2012-04-15
JP2009280592A (ja) 2009-12-03
ES2343115T3 (es) 2010-07-23
DE602004026415D1 (de) 2010-05-20
EP2075249A2 (en) 2009-07-01
ATE463491T1 (de) 2010-04-15
EP2075249A3 (en) 2009-09-02
WO2004072062A3 (en) 2004-11-04
CA2513613A1 (en) 2004-08-26
BRPI0407512A (pt) 2006-02-14
EP2075249B1 (en) 2012-03-28
EP1597250B1 (en) 2010-04-07
WO2004072062A2 (en) 2004-08-26
ES2385071T3 (es) 2012-07-17
US7820672B2 (en) 2010-10-26
CN100439359C (zh) 2008-12-03
CN1742005A (zh) 2006-03-01
EP1597250A2 (en) 2005-11-23
PT1597250E (pt) 2010-06-25
EP1597250B8 (en) 2010-05-19
JP2006515004A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
GB0303319D0 (en) Organic compounds
ECSP12006206A (es) Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
EP1705988A4 (en) IMMUNOMODULATING COMPOUNDS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
GB2418025B (en) Device for the prevention or treatment of ulcers
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
GB0329874D0 (en) Compounds useful for the treatment of diseases
GB0416508D0 (en) Therapeutic agents
PL1900362T3 (pl) Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
TW200630367A (en) Substituted adenines and the uses thereof
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
GB0410238D0 (en) Therapeutic agents
GB2388027B (en) Use of palatinose for the treatment of mental stress
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
ZA200803101B (en) 4-oxadiozolyl-piperidine compounds and use thereof
TW200613301A (en) Novel amino-halogen-imidazopyridines
ZA200407501B (en) &#34;The treatment of sludge&#34;.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)